Neurology 2000;54:1848-1850
© 2000 American Academy of Neurology
Brief Communications
Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study
M. C. Walter, MD,
H. Lochmüller, MD,
P. Reilich, MD,
T. Klopstock, MD,
R. Huber, MD,
M. Hartard, MD,
M. Hennig, MSc,
D. Pongratz, MD and
W. Müller–Felber, MD
From the Friedrich-Baur-Institute (Drs. Walter, Lochmüller, Reilich, Pongratz, and Müller–Felber), Departments of Neurology (Dr. Klopstock) and Pulmonology (Dr. Huber), Ludwig-Maximilians-University of Munich; and the Department of Sports Medicine (Dr. Hartard), Institute for Medical Statistics and Epidemiology (M. Hennig), Technical University of Munich, Germany.
Address correspondence and reprint requests to Dr. Maggie C. Walter, Friedrich-Baur-Institute, Medizinische Klinik, Ziemssenstr. 1a, 80336 München, Germany; e-mail: Maggie.Walter{at}lrz.uni-muenchen.de
The authors assessed the safety and efficacy of creatine monohydrate (Cr) in various types of muscular dystrophies in a double-blind, crossover trial. Thirty-six patients (12 patients with facioscapulohumeral dystrophy, 10 patients with Becker dystrophy, 8 patients with Duchenne dystrophy, and 6 patients with sarcoglycan-deficient limb girdle muscular dystrophy) were randomized to receive Cr or placebo for 8 weeks. There was mild but significant improvement in muscle strength and daily-life activities by Medical Research Council scales and the Neuromuscular Symptom Score. Cr was well tolerated throughout the study period.
Key words: Creatine—Therapy—Muscular dystrophy—Dietary supplement
This article has been cited by other articles:
|
|
|
|
 
U. Schlattner, F. Gehring, N. Vernoux, M. Tokarska-Schlattner, D. Neumann, O. Marcillat, C. Vial, and T. Wallimann
C-terminal Lysines Determine Phospholipid Interaction of Sarcomeric Mitochondrial Creatine Kinase
J. Biol. Chem.,
June 4, 2004;
279(23):
24334 - 24342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Tarnopolsky, D. J. Mahoney, J. Vajsar, C. Rodriguez, T. J. Doherty, B. D. Roy, and D. Biggar
Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy
Neurology,
May 25, 2004;
62(10):
1771 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kirschner and C. G. Bonnemann
The Congenital and Limb-Girdle Muscular Dystrophies: Sharpening the Focus, Blurring the Boundaries
Arch Neurol,
February 1, 2004;
61(2):
189 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Tarnopolsky, J. M. Bourgeois, R. Snow, S. Keys, B. D. Roy, J. M. Kwiecien, and J. Turnbull
Histological assessment of intermediate- and long-term creatine monohydrate supplementation in mice and rats
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2003;
285(4):
R762 - R769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Eijnde, M. Van Leemputte, M. Goris, V. Labarque, Y. Taes, P. Verbessem, L. Vanhees, M. Ramaekers, B. Vanden Eynde, R. Van Schuylenbergh, et al.
Effects of creatine supplementation and exercise training on fitness in men 55-75 yr old
J Appl Physiol,
August 1, 2003;
95(2):
818 - 828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schneider-Gold, M. Beck, C. Wessig, A. George, H. Kele, K. Reiners, and K. V. Toyka
Creatine monohydrate in DM2/PROMM: A double-blind placebo-controlled clinical study
Neurology,
February 11, 2003;
60(3):
500 - 502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Persky, M. Muller, H. Derendorf, M. Grant, G. A. Brazeau, and G. Hochhaus
Single- and Multiple-Dose Pharmacokinetics of Oral Creatine
J. Clin. Pharmacol.,
January 1, 2003;
43(1):
29 - 37.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Walzel, O. Speer, E. Boehm, S. Kristiansen, S. Chan, K. Clarke, J. P. Magyar, E. A. Richter, and T. Wallimann
New creatine transporter assay and identification of distinct creatine transporter isoforms in muscle
Am J Physiol Endocrinol Metab,
August 1, 2002;
283(2):
E390 - E401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vorgerd, J. Zange, R. Kley, T. Grehl, A. Husing, M. Jager, K. Muller, R. Schroder, W. Mortier, K. Fabian, et al.
Effect of High-Dose Creatine Therapy on Symptoms of Exercise Intolerance in McArdle Disease: Double-blind, Placebo-Controlled Crossover Study
Arch Neurol,
January 1, 2002;
59(1):
97 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hespel, B. Op't Eijnde, M. V. Leemputte, B. Urso, P. L Greenhaff, V. Labarque, S. Dymarkowski, P. V. Hecke, and E. A Richter
Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans
J. Physiol.,
October 15, 2001;
536(2):
625 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Doherty, K. Lougheed, J. Markez, and M. A. Tarnopolsky
Creatine monohydrate does not increase strength in patients with hereditary neuropathy
Neurology,
August 14, 2001;
57(3):
559 - 560.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Persky and G. A. Brazeau
Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate
Pharmacol. Rev.,
May 11, 2001;
(2001)
1.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. O.'t Eijnde, B. Urso, E.A. Richter, P.L. Greenhaff, and P. Hespel
Effect of Oral Creatine Supplementation on Human Muscle GLUT4 Protein Content After Immobilization
Diabetes,
January 1, 2001;
50(1):
18 - 23.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Klopstock, V. Querner, F. Schmidt, F. Gekeler, M. Walter, M. Hartard, M. H. Dipl-Stat, T. Gasser, D. Pongratz, A. Straube, et al.
A placebo-controlled crossover trial of creatine in mitochondrial diseases
Neurology,
December 12, 2000;
55(11):
1748 - 1751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Persky and G. A. Brazeau
Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate
Pharmacol. Rev.,
June 1, 2001;
53(2):
161 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
